Suzhou, China, May 16, 2021 —Kintor Pharmaceutical Limited (HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced the appointment of Dr. Qun Lu as the Chief Technology Officer (CTO) and Dr. Jiawen Han as vice president of business development. Dr. Lu will be primarily responsible for Chemistry, Manufacturing, and Control (the “CMC”) including drug analysis, formulation development and the production. Dr. Han will be primarily responsible for business development-related projects and management. Both of Dr. Lu and Dr. Han will be reporting to Dr. Youzhi Tong, Founder, Chairman, and CEO of Kintor Pharmaceuticals.

Dr. Youzhi Tong, Founder, Chairman, and CEO of Kintor Pharmaceuticals, commented, "We are pleased to welcome Dr. Lu and Dr. Han to help drive Kintor’s success. Dr. Lu has extensive international experience in the field of pharmaceutical chemistry, manufacturing, and quality control. Dr. Han has extensive experience in business development. The addition of these two professionals will help Kintor Pharmaceuticals further accelerate product commercialization and fulfill our mission of becoming a leader in the research, development, and commercialization of innovative therapies that benefit patients and improve global health."

Dr. Lu has over 20 years of experience in biopharmaceutical industry with proven track record of successfully leading the CMC development of pharmaceutical dosage forms from discovery through commercialisation at various pharmaceutical corporations including Pfizer, Merck and Celgene Corp./Bristol Myers Squibb (the “BMS”). Prior to joining the Group, Dr. Lu was an executive director at Celgene Corp./BMS in New Jersey from 2013 to 2019 and from 2019 to April 2021 respectively, where she focused on defining and delivering integrated CMC development strategies and outcomes for innovative medicines. She carried out post-doctoral studies in Pharmaceutics at the University of Wisconsin – Madison from 1996 to 1997. She also served as a member of the board of directors of International Consortium for Innovation and Quality in Pharmaceutical Development until 2019. Dr. Lu received her bachelor degree in Chemistry from Peking University in 1987 and completed her Ph.D. in Physical Chemistry at Arizona State University in 1995.

Dr. Han has over 25 years of experience in drug development and business operations in the pharmaceuticals industry. He served as a vice president in Qilu Boston LLC in Boston and in Wuxi AppTec Pharmaceutical Inc, in Shanghai from September 2017 to May 2021 and from January 2014 to May 2017 respective. From 1995 to 2013, he held important roles and positions in various companies, including AstraZeneca R&D Innovation Center China (ICC) in Shanghai, Aileron Therapheutics, Inc. in Cambridge, ImmunoGen Inc. in Cambridge and Apoptosis Technology Inc. in Cambridge. He was also a Postdoctoral Associate in department of Biology in Massachusetts Institute of Technology in Cambridge from 1992 to 1994. Dr. Han received his doctor degree in Medicine from Peking University in Beijing, the PRC in 1986 and subsequently a Doctor of Philosophy in Biochemistry from University of Rochester School of Medicine in New York in 1992.